Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Overview of attention for article published in The Lancet, June 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 19 X users

patent: 30 patents
facebook: 1 Facebook page
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 327 Mendeley
citeulike: 1 CiteULike
connotea: 1 Connotea

So far, Altmetric has seen 22 X posts from 19 X users, with an upper bound of 831,613 followers.

@Bidenhasfailedu @DrNeilStone Immunotherapies (teplizumab) delay T1D but don’t reverse it. Rituximab/abatacept show short-term effects. Vertex’s stem cells require immunosuppression. No cure yet. https://t.co/8QqvfNW4U5) https://t.co/wySIXeOoMs)

clinical trial using abatacept (CTLA4-Ig) in type 1 diabetes, some improvement http://t.co/YOzOEfxfTu

7. Abatacept (CTLA4 Ig) preserves C-peptide levels in type 1 diabetics http://t.co/jCIHmfqF #diabetes

Co-estimulação de modulação com abatacept em pacientes com início recente de DM 1 (Lancet) http://t.co/FcYRPnrM

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.